GlassScriptPhysician profile
Shivjit S Gill
NPI 1639404551
$7,490.93
in general payments reported to CMS, 2019-2025
43 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $874 · 2021: $995 · 2022: $1,114 · 2023: $1,509 · 2024: $731 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,183.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $806.38 | 2021-2025 | |
| Pfizer INC. | $563.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $514.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $509.81 | 2022-2025 | |
| Lilly USA, LLC | $479.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $423.58 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.90 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $204.89 | 2019-2021 | |
| Abbott Laboratories | $202.21 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.64 | 2019-2024 | Jardiance |
| Amgen INC. | $165.83 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $164.95 | 2019-2025 | Arexvy, Shingrix |
| Allergan, INC. | $141.19 | 2019-2020 | |
| Esperion Therapeutics, INC. | $125.39 | 2020-2023 | Nexletol |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivjit Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.